Navigation Links
PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition

SCHOFIELD, Wis., May 30, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an online interview to discuss recent developments, and the potential acquisition of a health and beauty products patent portfolio.

Highlights of the almost seven-minute interview, include:

  • Revenue Potential for LipiGesic® M Could Exceed $50 Million
  • Expanding Retail Chain-Store Distribution
  • Expansion into International Markets
  • Potential Patent Portfolio Acquisition Worth Millions
  • Market Capitalization Currently under $1 Million

Revenue Potential
Russ Mitchell , the Chairman and CEO of PuraMed BioScience, commented that with nearly 60 million Americans suffering from migraines the revenue potential for LipiGesic M, their over-the-counter migraine pain relief product, could generate over $50 million in sales annually by capturing just 1 percent of the migraine market.

Mr. Mitchell also discussed expanding distribution for their over-the-counter migraine pain reliever product, LipiGesic M, which is currently available in approximately 15,000 Walgreen's and CVS/pharmacy stores in all 50 states in the United States. According to Mr.Mitchell, he expects LipiGesic M to expand distribution into additional chains and wholesalers including all major retailers known to carry health and beauty products.

Off air, Mr. Mitchell said, "This expanded distribution would include mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains, which would add approximately another 21,000 stores."

In addition to US distribution, PuraMed BioScience has received its initial order from Columbia and has plans to expand to other Latin American countries as well as other regions around the world.

Patent Portfolio Acquisition
In the interview, Mr. Mitchell discussed current negotiations to acquire a patent portfolio of products in the anti-inflammatory, anti-bacterial, and anti-viral categories. Upon completion of the acquisition, PuraMed BioScience intends to license some of these patents to larger key manufacturers or bring these products to market directly. Mr. Mitchell commented, "Each one of those categories is huge, and has the potential to bring in many millions of dollars of additional revenue as these products get placed into the market."

To access the online interview please visit

About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M,, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders.

Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Melissa Diaz ,
South Street Media, Inc
Phone: (917) 937-8968

SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
9. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
10. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
11. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):